发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Navigating AML treatment in vascular Ehlers-Danlos syndrome: achieving deeper remission with oral azacitidine-a first case report. 在血管性埃勒-丹洛斯综合征中导航AML治疗：口服阿扎胞苷实现更深程度的缓解——首例报告
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-24 DOI: 10.1080/10428194.2024.2438807
Verna Cheung, Shannon Nixon, Nimish Mittal, Hassan Sibai
{"title":"Navigating AML treatment in vascular Ehlers-Danlos syndrome: achieving deeper remission with oral azacitidine-a first case report.","authors":"Verna Cheung, Shannon Nixon, Nimish Mittal, Hassan Sibai","doi":"10.1080/10428194.2024.2438807","DOIUrl":"10.1080/10428194.2024.2438807","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"785-789"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. 多发性骨髓瘤的风险适应治疗：评估当前的潜力和未来的路线图。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-22 DOI: 10.1080/10428194.2024.2443550
Saurabh Zanwar, Shaji Kumar
{"title":"Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future.","authors":"Saurabh Zanwar, Shaji Kumar","doi":"10.1080/10428194.2024.2443550","DOIUrl":"10.1080/10428194.2024.2443550","url":null,"abstract":"<p><p>Over the past two decades, new agents for multiple myeloma (MM) have significantly improved patient outcomes, particularly for those with standard-risk disease, who now have a median overall survival of over a decade. However, this benefit is less pronounced in high-risk and ultra-high-risk MM, where median survival ranges from 3 to 5 years. The definition of HRMM continues to evolve and is driven by the genomic features, disease burden, and medical comorbidities. Various risk stratification tools are available to gauge the risk status of the disease. Recently, a slew of single-arm phase 2 trials for high-risk MM have been reported with a general theme of intensification of various phases of treatment. Additionally, minimal residual disease testing in treatment escalation/de-escalation is being actively investigated. This review summarizes the existing evidence for risk-adapted treatment in patients with MM.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"573-583"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation. 社区和移植中心之间的共享护理模式有助于获得同种异体和自体移植。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-06 DOI: 10.1080/10428194.2024.2434171
Joshua A Fein, Agnes McAuliffe, Kimberly Fischer, Owen Brady, Sean M Devlin, Silvia Willumsen, Gonca Ozcan, Pat Montanaro, Yelena Pristyazhnyuk, Joseph DiGiuseppe, Oscar B Lahoud, Miguel-Angel Perales, David G Pfister, Sergio Giralt, Mark Dailey, Peter Paul Yu, Craig Steven Sauter
{"title":"A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation.","authors":"Joshua A Fein, Agnes McAuliffe, Kimberly Fischer, Owen Brady, Sean M Devlin, Silvia Willumsen, Gonca Ozcan, Pat Montanaro, Yelena Pristyazhnyuk, Joseph DiGiuseppe, Oscar B Lahoud, Miguel-Angel Perales, David G Pfister, Sergio Giralt, Mark Dailey, Peter Paul Yu, Craig Steven Sauter","doi":"10.1080/10428194.2024.2434171","DOIUrl":"10.1080/10428194.2024.2434171","url":null,"abstract":"<p><p>Access to allogeneic and autologous hematopoietic stem cell transplantation (SCT) remains inadequate despite its curative potential across hematologic malignancies. In 2015, Hartford HealthCare (HHC) and the Memorial Sloan Kettering Cancer Center (MSK) established the Shared Care Model (SCM) with a primary aim of enhancing SCT access for HHC patients. The SCM comprises several components: an SCT-dedicated nurse-navigator, a health-information exchange for record sharing, telemedicine, and ongoing training of HHC clinicians in transplant patient selection and management. We evaluated the SCM's impact on SCT access across 126 patients with acute leukemia, myelodysplastic syndrome, and multiple myeloma from 2016-2020. The SCM facilitated 34 referrals. Socio-economic status of HHC referrals by Area Deprivation Index was significantly inferior (38 vs. 14, <i>p</i> < 0.001) when compared to 3,108 non-SCM referrals to MSK during the same period. Allogeneic recipients spent 68-247 days away from home, and autologous recipients 15-48, both requiring few subsequent visits to MSK.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"713-720"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study. 德国复发/难治性多发性骨髓瘤患者接受卡非佐米联合治疗的依从性和有效性：非介入性CARO研究的中期结果
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-09 DOI: 10.1080/10428194.2024.2436034
Wolfgang Knauf, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Andreas Ammon, Arnd Nusch, Rudolf Schlag, Holger Schulz, Jan Janssen, Manfred Welslau, Stefan Wilop, Corinne Vannier, Hans Ulrich Siebenbach, Laura Serrer, Anita Schuch, Sandra Maria Woerner, Monika Engelhardt, Karin Potthoff
{"title":"Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.","authors":"Wolfgang Knauf, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Andreas Ammon, Arnd Nusch, Rudolf Schlag, Holger Schulz, Jan Janssen, Manfred Welslau, Stefan Wilop, Corinne Vannier, Hans Ulrich Siebenbach, Laura Serrer, Anita Schuch, Sandra Maria Woerner, Monika Engelhardt, Karin Potthoff","doi":"10.1080/10428194.2024.2436034","DOIUrl":"10.1080/10428194.2024.2436034","url":null,"abstract":"<p><p>Therapy adherence can significantly influence the outcome of cancer patients. The prospective, non-interventional CARO study (NCT02970747) investigated adherence, effectiveness, and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in the German real-world setting. In total, 359 patients were included at 69 sites. Data on carfilzomib combination regimens were evaluated for three treatment cohorts: carfilzomib with lenalidomide and dexamethasone (KRd), with dexamethasone only (Kd) or with daratumumab and dexamethasone (KdD). Encouragingly, patients maintained levels of treatment adherence ≥95% to carfilzomib across cohorts. The effectiveness outcomes of CARO were in line with previous data. Median PFS (95% CI) was 17.5 months (14.5, 24.7 [KRd]), 13.4 months (7.0, 18.1 [Kd]), and 15.6 months (9.9, NA [KdD]), respectively. Median OS was 38.9 months (31.5, 53.9 [KRd]), 24.2 months (17.3, 36.8 [Kd]), and not reached (KdD). Overall, the CARO study impressively demonstrates efficacy and safety of KRd, Kd, and KdD regimen in real-world.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"691-701"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern. 单细胞分析显示双克隆慢性淋巴细胞白血病的两个克隆具有不同的基因表达模式。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1080/10428194.2024.2438804
Maria Dampmann, Artur Kibler, Julia von Tresckow, Hans Christian Reinhardt, Ralf Küppers, Bettina Budeus
{"title":"Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.","authors":"Maria Dampmann, Artur Kibler, Julia von Tresckow, Hans Christian Reinhardt, Ralf Küppers, Bettina Budeus","doi":"10.1080/10428194.2024.2438804","DOIUrl":"10.1080/10428194.2024.2438804","url":null,"abstract":"<p><p>Dual productive B-cell receptor (BCR) rearrangements have been repeatedly reported for chronic lymphocytic leukemia (CLL), but the standard population-based PCR analyses cannot distinguish whether these are bi-clonal CLL, or a monoclonal CLL with bi-allelic productive rearrangements. We investigated CLL cells by combined single-cell RNA and BCR sequencing. We identified two CLL clones using different immunoglobulin (Ig) heavy-chain V region genes (IGHV) genes and distinct Ig λ light chains. One clone is classified as Ig unmutated the other as mutated. The two CLL clones have distinct transcriptomes: Numerous genes were differentially expressed, with genes typical for unmutated or mutated CLL showing the expected representation in the two clones. Using PCR, cloning and Sanger sequencing of the IGHV rearrangements we detected both CLL clones over a period of three years without clinical progression of the CLL and thus giving insights into the disease biology of multi-clonal CLL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"744-752"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia. Venetoclax联合氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和依达柔比星（FLAG-Ida）治疗血统不明的急性白血病和急性淋巴细胞白血病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2025-01-16 DOI: 10.1080/10428194.2024.2443017
Steven Tessier, Kristen B McCullough, Naseema Gangat, Kebede H Begna, Antoine N Saliba, Abhishek A Mangoankar, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Aref Al-Kali, Hassan B Alkhateeb
{"title":"Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.","authors":"Steven Tessier, Kristen B McCullough, Naseema Gangat, Kebede H Begna, Antoine N Saliba, Abhishek A Mangoankar, Mithun V Shah, William J Hogan, Mrinal M Patnaik, Aref Al-Kali, Hassan B Alkhateeb","doi":"10.1080/10428194.2024.2443017","DOIUrl":"10.1080/10428194.2024.2443017","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"780-784"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation. 原发性骨髓纤维化和RUNX1种系突变患者的巨核细胞中心体和高尔基体结构紊乱。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-09 DOI: 10.1080/10428194.2024.2438801
Ifeyinwa E Obiorah, Debamita Kundu, Folashade Adekunle, Patcharin Pramoonjago, Katherine R Calvo, Paul Liu, Adam Goldfarb
{"title":"Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with <i>RUNX1</i> germline mutation.","authors":"Ifeyinwa E Obiorah, Debamita Kundu, Folashade Adekunle, Patcharin Pramoonjago, Katherine R Calvo, Paul Liu, Adam Goldfarb","doi":"10.1080/10428194.2024.2438801","DOIUrl":"10.1080/10428194.2024.2438801","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"797-800"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning. 同种异体干细胞移植治疗侵袭性淋巴瘤：骨髓清除后外周血t细胞淋巴瘤和弥漫性大b细胞淋巴瘤的移植物抗淋巴瘤作用
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-11 DOI: 10.1080/10428194.2024.2438805
Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
{"title":"Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning.","authors":"Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf","doi":"10.1080/10428194.2024.2438805","DOIUrl":"10.1080/10428194.2024.2438805","url":null,"abstract":"<p><p>Allogeneic stem cell transplantation (alloSCT) represents a curative option for patients with relapsed/refractory (r/r) aggressive lymphomas. We compared outcomes of alloSCT in r/r PTCL and r/r DLBCL pts (<i>n</i> = 150) who underwent identical myeloablative conditioning chemotherapy, GvHD prophylaxis, and relapse management. 5-year PFS and OS were significantly superior in PTCL compared to DLBCL (56% vs. 24%; 56% vs. 28%; <i>p</i> ≤ 0.005). A landmark analysis (day≥ +100 post-alloSCT) markedly favored outcomes in PTCL vs. DLBCL: 5-year PFS and OS of 76% vs. 30% and 76% and 35%, respectively (<i>p</i> ≤ 0.003). Non-relapse mortality was comparable (35% PTCL vs. 34% DLBCL, <i>p</i> = 0.894), whereas post-alloSCT relapse mortality was significantly higher in DLBCL (36% vs. 10%, <i>p</i> = 0.0007). The occurence of limited chronic GvHD did not improve outcomes in DLBCL, whereas extensive chronic GvHD was a negative risk factor for both (HR 2.09 and 2.80, <i>p</i> ≤ 0.006). In conclusion, we gained evidence for strong graft-versus-lymphoma activity against PTCL but not DLBCL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"668-679"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia. ML385 是一种 Nrf2 选择性抑制剂，在治疗成人 T 细胞白血病方面具有疗效。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1080/10428194.2024.2441875
Chie Ishikawa, Naoki Mori
{"title":"ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.","authors":"Chie Ishikawa, Naoki Mori","doi":"10.1080/10428194.2024.2441875","DOIUrl":"10.1080/10428194.2024.2441875","url":null,"abstract":"<p><p>Nrf2 plays a critical role in regulating cytoprotective transcriptional responses and glucose metabolism while also preventing inflammation-induced carcinogenesis. However, Nrf2 can paradoxically promote carcinogenesis. Here, we aimed to elucidate the role of Nrf2 in ATL associated with HTLV-1. HTLV-1-infected T-cell lines exhibited nuclear accumulation of Nrf2. Nrf2 knockdown along with the inhibition of its activity using ML385, decreased cell proliferation and survival. Furthermore, ML385-induced G1 arrest by enhancing γH2AX and p53 expression while downregulating CDK4/6, cyclin D2/E, and c-Myc. Additionally, ML385 triggered caspase-mediated apoptosis by downregulating the expression of anti-apoptotic proteins while upregulating pro-apoptotic proteins. The compound also induced necroptosis, promoted JNK phosphorylation, and inhibited the NF-κB, AP-1, and STAT3/5 signaling. Moreover, ML385 was found to reduce the expression of LDHA, glucose uptake, and the levels of lactate derived from glycolysis. Overall, these results suggest that Nrf2 functions as an oncogene in ATL and may represent a promising therapeutic target.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"721-732"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spontaneous regression of cutaneous T cell lymphoma in an HIV-positive patient. hiv阳性患者皮肤T细胞淋巴瘤的自发消退。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-02 DOI: 10.1080/10428194.2024.2433616
Xin Yun Teoh, Mazliha Mashor Mansor, Azura Mohd Affandi, Asmawiza Awang, Zuliatul Faizah Baharom
{"title":"Spontaneous regression of cutaneous T cell lymphoma in an HIV-positive patient.","authors":"Xin Yun Teoh, Mazliha Mashor Mansor, Azura Mohd Affandi, Asmawiza Awang, Zuliatul Faizah Baharom","doi":"10.1080/10428194.2024.2433616","DOIUrl":"10.1080/10428194.2024.2433616","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"794-796"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信